Liu Zhenwei, Tang Guolu, Peng Yinghui, Lan Jixian, Xian Yuting, Tian Xingui, Chen Dehui
Department of Pediatrics, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
State Key Laboratory of Respiratory Disease, Guangdong-Hong Kong-Macao Joint Laboratory of Respiratory Infectious Disease, Guangzhou Medical University, Guangzhou, China.
Heliyon. 2024 Aug 3;10(15):e35783. doi: 10.1016/j.heliyon.2024.e35783. eCollection 2024 Aug 15.
Human adenovirus (HAdV) type 40 in species F (HAdV-F40) and HAdV-F41 represent the third most prevalent causative agents of non-bacterial acute gastroenteritis in infants and young children, following norovirus and rotavirus. Despite their significant contribution to global child morbidity, vaccines to preemptively combat these viruses remain elusive. In this study, we investigate the potential for cross-neutralization between HAdV-F40 and HAdV-F41 using immune sera with the short fiber knob (SFK). We implemented a series of assays to evaluate the responses, including enzyme-linked immunosorbent, micro-neutralization, immunofluorescence, and quantitative polymerase chain reaction. Our results demonstrate that immune sera with HAdV-F40 SFK or HAdV-F41 SFK could effectively neutralize both HAdV-F40 and HAdV-F41, indicating a mutual cross-neutralizing effect. Notably, the immune sera with HAdV-F40 SFK demonstrated a stronger neutralization effect, suggesting the potential to develop a subunit vaccine that can simultaneously counteract both viruses. These findings underscore the potential of SFK immunization in evoking a cross-neutralizing antibody response between HAdV-F40 and HAdV-F41. This suggests a promising avenue for developing subunit vaccines against HAdV-F40 and HAdV-F41 and provides a novel perspective on the potential of neutralizing antibodies to protect against these two types of HAdV.
F 种人类腺病毒（HAdV）中的 40 型（HAdV-F40）和 HAdV-F41 是婴幼儿非细菌性急性肠胃炎的第三大常见病原体，仅次于诺如病毒和轮状病毒。尽管它们对全球儿童发病率有重大影响，但用于预防这些病毒的疫苗仍然难以捉摸。在本研究中，我们使用具有短纤维钮（SFK）的免疫血清研究了 HAdV-F40 和 HAdV-F41 之间交叉中和的潜力。我们实施了一系列试验来评估反应，包括酶联免疫吸附试验、微量中和试验、免疫荧光试验和定量聚合酶链反应。我们的结果表明，含有 HAdV-F40 SFK 或 HAdV-F41 SFK 的免疫血清可以有效中和 HAdV-F40 和 HAdV-F41，表明存在相互交叉中和作用。值得注意的是，含有 HAdV-F40 SFK 的免疫血清表现出更强的中和作用，这表明有开发一种能同时对抗这两种病毒的亚单位疫苗的潜力。这些发现强调了 SFK 免疫在引发 HAdV-F40 和 HAdV-F41 之间交叉中和抗体反应方面的潜力。这为开发针对 HAdV-F40 和 HAdV-F41 的亚单位疫苗提供了一条有前景的途径，并为中和抗体预防这两种 HAdV 的潜力提供了新的视角。
